Bristol Myers Squibb (BMS) has partnered with NVIDIA to construct the largest AI supercomputer in the pharmaceutical sector, expected to be operational by January 2027. This supercomputer will be hosted by Equinix under a co-location agreement, marking a significant investment in AI technology for drug discovery.
The initiative underscores the growing importance of high-performance computing in pharmaceuticals, as companies recognize that computational power is essential for advancing drug discovery processes. Unlike tech firms that rent computing resources, BMS has opted to purchase its own infrastructure, ensuring control over proprietary data and intellectual property.
Looking ahead, BMS's AI supercomputer will feature NVIDIA's DGX SuperPOD, significantly enhancing performance and providing access to advanced AI tools. This strategic move aligns with BMS's commitment to leveraging AI for improved patient outcomes, as highlighted by Chief Digital and Technology Officer Greg Meyers. No further timeline was disclosed at the time of publication.
Editor's Note
The collaboration between Bristol Myers Squibb and NVIDIA highlights a pivotal shift in the pharmaceutical industry towards in-house computing capabilities. As AI continues to reshape drug discovery, companies are recognizing the need for robust infrastructure to support their research initiatives. This trend may influence procurement strategies across the sector, as firms weigh the benefits of ownership versus rental of computing resources.
Leave a comment